MedTrace Logo

Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC

NCT06769971 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-01-10

No results posted yet for this study

Summary

This is a phase II study. All patients are treatment naive extensive stage small cell lung cancer(ES-SCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of Ivonescimab and Cadonilimab in combination with chemotherapy in patients with ES-SCLC.

Conditions

Interventions

DRUG

Ivonescimab

20mg/kg，IV infusion，Day1，Q3W

DRUG

Cadonilimab

10mg/kg，IV infusion，Day8，Q6W

DRUG

Etoposide

100mg/kg，IV infusion，Day1-3，Q3W

DRUG

Carboplatin

AUC 5，IV infusion，Day1，Q3W

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • Yongsheng Wang, Prof · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06769971 on ClinicalTrials.gov